Last edition
News about "Docetaxel"
Astellas Advances Setidegrasib Into Phase 3 Trial for NSCLC
Astellas has dosed the first patient in a Phase 3 study evaluating setidegrasib against docetaxel in patients with KRAS G12D-mutated NSCLC.
Docetaxel | 25/09/2026 | By News Bureau | 132
BioNTech and OncoC4 Report Survival Benefit with Gotistobart in Squamous NSCLC
BioNTech and OncoC4 report updated phase 3 data showing gotistobart improved median Overall Survival (OS) to 18.5 months versus 10 months with chemotherapy in previously treated squamous NSCLC.
Docetaxel | 14/09/2026 | By News Bureau | 155
Venus Remedies secures marketing authorisation for key cancer drugs from Philippines, Paraguay, Georgia and Moldova; strengthens global presence
Docetaxel | 01/08/2023 | By Sudeep Soparkar | 1138
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy